Liposomal iron bisglycinate hydrochloride, but not free iron bisglycinate, enhances serum iron restoration in a mouse model of inflammation-induced anemia: a preliminary study.

Abstract

Iron deficiency is a major global health concern, particularly in inflammation-related anemia (IRA), where iron absorption and mobilization are impaired. Liposomal encapsulation may help enhance the bioavailability and efficacy of iron supplements. This study aimed to evaluate the therapeutic efficacy of orally administered liposomal iron bisglycinate hydrochloride (LIBH), compared to free iron bisglycinate hydrochloride (FIBH), in restoring serum iron levels in a mouse model of lipopolysaccharide (LPS)-induced anemia of inflammation (LIAI). Male C57BL/6 mice received intraperitoneal LPS (5 mg/kg) to induce LIAI and were simultaneously treated with either FIBH or LIBH (1 mg/kg, oral). Liposomes (150-200 nm) exhibited high encapsulation efficiency (93%) and stability (-38 to -45 mV zeta potential). Serum iron levels were measured 24 hours post-treatment. LPS administration significantly reduced serum iron levels. LIBH restored serum iron levels by 35 - 65% compared to baseline (p < 0.005), outperforming FIBH (0 - 16%, p = NS). Electron microscopy confirmed the structural integrity of LIBH liposomes. It seems that LIBH supplementation significantly improves serum iron levels in LIAI and may represent a superior alternative to traditional free iron therapy, particularly in inflammatory conditions. Further studies are warranted to assess its efficacy in other models of anemia.